Literature DB >> 28798511

Safety concerns with the direct-acting antivirals for hepatitis C.

Alain Braillon1.   

Abstract

Year:  2017        PMID: 28798511      PMCID: PMC5478404          DOI: 10.18773/austprescr.2017.036

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


× No keyword cloud information.
  4 in total

Review 1.  Managing hepatitis C in general practice.

Authors:  Simone I Strasser
Journal:  Aust Prescr       Date:  2017-04-03

2.  Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.

Authors:  Sujan Ravi; Page Axley; DeAnn Jones; Sudha Kodali; Heather Simpson; Brendan M McGuire; Ashwani K Singal
Journal:  Gastroenterology       Date:  2017-02-02       Impact factor: 22.682

3.  Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study.

Authors:  Dimitrios Trichopoulos; Christina Bamia; Pagona Lagiou; Veronika Fedirko; Elisabeth Trepo; Mazda Jenab; Tobias Pischon; Ute Nöthlings; Kim Overved; Anne Tjønneland; Malene Outzen; Francoise Clavel-Chapelon; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Krasimira Aleksandrova; Vassiliki Benetou; Dimosthenis Zylis; Domenico Palli; Valeria Pala; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; H Bas Bueno-De-Mesquita; Henk J Van Kranen; Petra H M Peeters; Eiliv Lund; J Ramón Quirós; Carlos A González; Maria-Jose Sanchez Perez; Carmen Navarro; Miren Dorronsoro; Aurelio Barricarte; Björn Lindkvist; Sara Regnér; Mårten Werner; Göran Hallmans; Kay-Tee Khaw; Nick Wareham; Timothy Key; Isabelle Romieu; Shu-Chun Chuang; Neil Murphy; Paolo Boffetta; Antonia Trichopoulou; Elio Riboli
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506

4.  DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.

Authors:  Rosanna Villani; Antonio Facciorusso; Francesco Bellanti; Rosanna Tamborra; Annamaria Piscazzi; Matteo Landriscina; Gianluigi Vendemiale; Gaetano Serviddio
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.